Last Update31 Jul 25Fair value Increased 15%
Sleep Number’s consensus price target has increased, primarily reflecting a meaningful rise in its forward P/E multiple despite stable net profit margins, raising the fair value estimate from $6.50 to $7.50.
What's in the News
- Sleep Number expects full year 2025 net sales of approximately $1.45 billion, reflecting an estimated 14% year-over-year decline.
- Bob Ryder appointed interim CFO; Francis Lee steps down but remains as advisor for the transition period.
- Shareholder attempts to declassify the board and eliminate supermajority voting requirements for directors and certain transactions failed, as required vote thresholds were not met.
- No shares were repurchased between December 29, 2024 and March 29, 2025; the company has completed the repurchase program initiated in 2006.
Valuation Changes
Summary of Valuation Changes for Sleep Number
- The Consensus Analyst Price Target has significantly risen from $6.50 to $7.50.
- The Future P/E for Sleep Number has significantly risen from 8.95x to 10.52x.
- The Net Profit Margin for Sleep Number remained effectively unchanged, moving only marginally from 1.40% to 1.37%.
Key Takeaways
- High debt and limited capital flexibility, combined with lack of near-term growth drivers, threaten margins and risk future earnings as macro pressures persist.
- Efforts to broaden distribution and simplify offerings could weaken brand differentiation and innovation, making Sleep Number vulnerable to intensified competition and commoditization.
- Enhanced marketing efficiency, cost discipline, product simplification, omni-channel expansion, and proprietary tech position Sleep Number for resilient growth, margin improvement, and broader market relevance.
Catalysts
About Sleep Number- Designs, manufactures, markets, distributes, retails, and services sleep solutions in the United States.
- Management signals a long path to top-line recovery despite ongoing cost cuts; with flat second-half revenues expected and no material growth initiatives realized until 2026, investor optimism around near-term revenue growth and operating leverage appears unfounded, putting forward multiples at risk. (Impacts: Future sales, operating margins)
- The company's strategy to broaden distribution-including digital-first, retail partnerships, and emerging platforms-may dilute brand differentiation and margin structure, especially as competition in smart bed and connected home categories intensifies and price pressure from commoditized DTC models increases. (Impacts: Gross margins, average selling price, long-term revenue growth)
- High debt burden and dependence on favorable lender negotiations continue to constrain capital allocation flexibility, making long-term investments in innovation or large-scale channel expansion riskier and increasing the likelihood of future margin and earnings compression if macro conditions or lender terms tighten. (Impacts: Interest expenses, net margins, long-term earnings)
- CEO and CFO emphasized needing to make the product assortment, pricing, and retail experience simpler and more accessible to reach a broader customer base, implicitly acknowledging that demographic shifts-such as the aging U.S. population, slower homeownership growth, and greater renting-are already pressuring Sleep Number's premium positioning and suppressing addressable market growth. (Impacts: Sales volume, average selling price, revenue growth)
- Rapid operational restructuring, including deep G&A and R&D cuts, risks eroding Sleep Number's innovation pipeline and long-term competitive moat, especially as larger industry trends drive increased integration of IoT, AI, and health-tracking into sleep products-potentially leading to brand commoditization and weaker gross margins if competitors outpace Sleep Number in R&D. (Impacts: Long-term gross margins, competitive positioning, innovation-driven revenue)
Sleep Number Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?- Analysts are assuming Sleep Number's revenue will decrease by 0.2% annually over the next 3 years.
- Analysts assume that profit margins will increase from -2.7% today to 1.6% in 3 years time.
- Analysts expect earnings to reach $23.9 million (and earnings per share of $0.93) by about August 2028, up from $-41.5 million today.
- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 10.7x on those 2028 earnings, up from -5.9x today. This future PE is lower than the current PE for the US Specialty Retail industry at 19.2x.
- Analysts expect the number of shares outstanding to grow by 1.79% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 12.32%, as per the Simply Wall St company report.
Sleep Number Future Earnings Per Share Growth
Risks
What could happen that would invalidate this narrative?- Significant improvements in marketing efficiency-including a 24% increase in conversion year-over-year and ongoing optimization of programs, channels, and customer targeting-could drive higher future revenue without proportionally increasing spend, boosting both top-line and margins over time.
- Aggressive cost reduction efforts ($130 million targeted in 2025) through streamlining G&A, R&D, and organizational layers, as well as supply chain and manufacturing efficiencies, have already led to improved EBITDA margins; further discipline in cost management may continue to expand net margins and earnings, even in a soft sales environment.
- Plans to enhance and simplify the product lineup, backed by proprietary sleep data and ongoing customer research, position the brand to broaden its addressable market and improve relevance and conversion, supporting future revenue growth as consumer demand for personalized wellness products rises.
- Commitment to omni-channel expansion-including new digital-first partnerships and a holistic ecosystem approach-has the potential to drive market share gains and reduce dependence on any single retail channel, supporting resilient revenue growth and potentially lowering distribution costs long-term.
- Strength in proprietary technology (SleepIQ®), historical gross margin improvements despite unit deleverage, and an explicit focus on innovation and product differentiation, position Sleep Number to benefit from ongoing secular trends in health, wellness, and connected home adoption, which could underpin long-term revenue and margin expansion.
Valuation
How have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of $7.5 for Sleep Number based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $1.5 billion, earnings will come to $23.9 million, and it would be trading on a PE ratio of 10.7x, assuming you use a discount rate of 12.3%.
- Given the current share price of $10.68, the analyst price target of $7.5 is 42.4% lower. Despite analysts expecting the underlying buisness to improve, they seem to believe the market's expectations are too high.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
How well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.